TVGN (Tevogen Bio Holdings) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Days Payable?

Tevogen Bio Holdings's average Accounts Payable for the three months ended in Sep. 2024 was $6.25 Mil. Tevogen Bio Holdings's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Tevogen Bio Holdings's Days Payable or its related term are showing as below:

TVGN's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 121.13
* Ranked among companies with meaningful Days Payable only.

Tevogen Bio Holdings's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Tevogen Bio Holdings Days Payable Historical Data

The historical data trend for Tevogen Bio Holdings's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Days Payable Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Days Payable

Tevogen Bio Holdings Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Tevogen Bio Holdings's Days Payable

For the Biotechnology subindustry, Tevogen Bio Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tevogen Bio Holdings's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tevogen Bio Holdings's Days Payable distribution charts can be found below:

* The bar in red indicates where Tevogen Bio Holdings's Days Payable falls into.

Save Embed

;

Save Embed

;

Tevogen Bio Holdings Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Tevogen Bio Holdings's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.21	+	1.142)	/	2 )	/	0	*	365
=	0.676					/	0	*	365
=	N/A

Tevogen Bio Holdings's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (6.666	+	5.838)	/	2 )	/	0	*	365 / 4
=	6.252					/	0	*	365 / 4
=	N/A

Tevogen Bio Holdings Days Payable Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (NAS:TVGN) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.